FML vaccine against canine visceral leishmaniasis: From second-generation to synthetic vaccine

Clarisa B. Palatnik-de-Sousa, André De Figueiredo Barbosa, Sandra Maria Oliveira, Dirlei Nico, Robson Ronney Bernardo, Wania R. Santos, Mauricio M. Rodrigues, Irene Soares, Gulnara P. Borja-Cabrera

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

43 Citas (Scopus)


The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune® vaccine for canine prophylaxis in Brazil. The immune response raised by the vaccine is long lasting, immunotherapeutic and reduces dog infectivity blocking the transmission of the disease, as revealed by an in vivo assay. The preliminary epidemiological control data of vaccinated areas in Brazil indicate that, in spite of the still low vaccine coverage, there was a significant decrease in the incidence of the human and canine disease. A 36-kDa glycoprotein, in the FML complex, is the human marker of the disease, which was protective in mice as native recombinant protein or DNA vaccine. The DNA vaccine is now being tested against the canine disease. This review resumes the development of the second-generation FML-saponin-Leishmune vaccine, its adjuvant and of the NH36 DNA vaccine, toward the identification of its major epitopes that might be included in a possible future synthetic vaccine.

Idioma originalInglés
Páginas (desde-hasta)833-851
Número de páginas19
PublicaciónExpert Review of Vaccines
EstadoPublicada - ago. 2008
Publicado de forma externa


Profundice en los temas de investigación de 'FML vaccine against canine visceral leishmaniasis: From second-generation to synthetic vaccine'. En conjunto forman una huella única.

Citar esto